Dr. Michael Duch, of Trenton Orthopaedic Group in New Jersey, discusses the final phase of the episode of care pilot program that involves devising an effective bundled payment model.
Additionally, Dr. Duch explains that the process is complex, given the significant amount of data that must be collected to fit the 3-month bundled payment model, including allowing for variations among patients with medical issues outside of orthopaedics.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More